CD8A and neoplasm: Administration of pleiotropic agent all-trans retinoic acid (ATRA) inhibits tumor-promoting signaling in activated PSCs, resulting in significantly increased infiltration of CD8+ T cells and improved therapeutic efficacy in PDAC models [131].